Aggravation of atonic seizures by rufinamide: A case report

Abstract Background Rufinamide is a novel antiepileptic drug used as adjunctive therapy in patients with Lennox–Gastaut syndrome and provides seizure control especially in tonic and atonic seizures. Rufinamide is expected to be effective in intractable epilepsy when atonic and tonic seizures exist....

Full description

Saved in:

Bibliographic Details
Published in:	Brain & development (Tokyo. 1979) Vol. 38; no. 7; pp. 654 - 657
Main Authors:	Bektas, Gonca, Caliskan, Mine, Aydin, Ali, Yildiz, Edibe Pembeguel, Tatli, Burak, Aydinli, Nur, Oezmen, Meral
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-08-2016
Subjects:	Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Atonic Benzodiazepines - therapeutic use Brain - drug effects Brain - physiopathology Child Drug Resistant Epilepsy - drug therapy Drug Resistant Epilepsy - physiopathology Drug Therapy, Combination Electroencephalography Humans Intractable epilepsy Male Neurology Piracetam - analogs & derivatives Piracetam - therapeutic use Rufinamide Seizure Seizures - drug therapy Seizures - physiopathology Triazoles - adverse effects Triazoles - therapeutic use Valproic Acid - therapeutic use Seizure Rufinamide Intractable epilepsy Atonic
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Background Rufinamide is a novel antiepileptic drug used as adjunctive therapy in patients with Lennox–Gastaut syndrome and provides seizure control especially in tonic and atonic seizures. Rufinamide is expected to be effective in intractable epilepsy when atonic and tonic seizures exist. However, rufinamide induced seizure aggravation has been reported in a few patients, which was not associated with a specific type of seizure. Case A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000 mg/day), levetiracetam (3000 mg/day) and clobazam (40 mg/day). Rufinamide was administered as adjuvant therapy. After 2 weeks on rufinamide, he experienced atonic seizure worsening, and the frequency of epileptic discharges increased. The deterioration in seizure frequency and epileptiform discharges resolved when rufinamide was discontinued. Conclusion Rufinamide may aggravate atonic seizures in patients with intractable epilepsy.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0387-7604 1872-7131
DOI:	10.1016/j.braindev.2016.02.005